Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Evaluation of Placental Transfusion Techniques in Prevention of Prematurity Related Complications and Effect on Their Hematological Profile

NCT06812507 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-03-10
Last updated
2026-01-16

Condition(s) studied

PrematurePlacental Transfusion

Investigational drug(s) / intervention(s)

intact umbilical milkingcut umbilical milkingDelayed cord clamping

intact umbilical milking: Umbilical cord milking will be performed by holding the newborn at or ∼20 cm below the level of the placenta. The cord will be pinched between 2 fingers as close to the placenta as possible and milked toward the infant over a 2-second duration. The cord will then be released and allowed to refill with blood for a brief 1- to 2-second pause between each milking motion. This will be repeated for 2-4 times. After completion, the cord will be clamped, and the neonate will be handed to the resuscitation team.

cut umbilical milking: Another technique, used more often in Asia, involves clamping and cutting a long segment of the umbilical cord immediately at birth and passing the baby and the long cord to the pediatric provider, called C-UCM untwists the cord and milks the entire contents into the baby. Milking the cord 2-3 times before clamping may produce a similar placental transfusion as C-UCM

Delayed cord clamping: Infants placed on the maternal abdomen or at the introitus below the level of placenta and waiting at least 30- to 60-second before clamping the cord.

Study summary

The objective of this study is to evaluate the general course and prognosis associated with different methods of placental transfusion (Intact umbilical cord milking, cut- umbilical cord milking and delayed cord clamping) in premature neonates over the first days of life

Eligibility

Sex
ALL
Min age
1 Minute
Max age
2 Minutes
Healthy volunteers
Accepted
* Inclusion Criteria: 1. Premature neonates ≤ 32 weeks gestational age regardless birth weight 2. patients should be admitted to neonatal intensive care unit in the first day of life of life Exclusion criteria: * Exclusion Criteria: Patient with any of the following will be excluded: 1. Major congenital anomalies (complex cyanotic heart disease, major central nervous system anomalies). 2. Evidence of head trauma causing major intracranial hemorrhage. 3. placental abnormalities like : abruptions, placenta previa or retroplacental hematoma. 4. Cord accident, or avulsion at the time of delivery. 5. Refusal to perform the intervention by the obstetrician

Primary outcome measure(s)

  • Hemoglobin level — on admission (In first day after birth),as well as, at end of first , second and third weeks of lives
    hemoglobin level will be measured in gram/dl

Trial sites (1)

FacilityCityRegionStatus
Marwa Mohamed Farag Alexandria Egypt Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06812507 on ClinicalTrials.gov ↗ ← All trials in Egypt